Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo App Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

Remotely Resolving Psychological Stress (Remote RePS)

NCT03196999
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Personalized Attention Bias Training, Neutral Attention Training Condition, Non-Personalized Attention Bias Training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 17, 2026, 2:36 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

NCT02569398
View directory record Official record
Conditions
Asymptomatic Amyloid-positive
Interventions
Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
557 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Early Phase 1 Interventional Results available

Neuroendocrine Risk for PTSD in Women

NCT03973229
View directory record Official record
Conditions
PTSD, Trauma
Interventions
Estradiol patch, Placebo patch
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 2:36 AM EDT
Not listed Not applicable Interventional

Viome Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions

NCT05563857
View directory record Official record
Conditions
Mental Health, Depression, Anxiety
Interventions
VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
Combination Product · Dietary Supplement
Lead sponsor
Viome
Industry
Eligibility
25 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 17, 2026, 2:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

NCT01689233
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TRx0237 200 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
58
States / cities
Phoenix, Arizona • Bellflower, California • Costa Mesa, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 17, 2026, 2:36 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00676143
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
111
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Evaluation of a Therapeutic Mobile App for Depression

NCT05601362
View directory record Official record
Conditions
Depression
Interventions
Gamified Attention Bias Modification, Gamified Placebo Training
Device
Lead sponsor
Christopher G. Beevers
Other
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 2:36 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Reducing Daily Stress Among Sexual and Gender Minorities

NCT05131360
View directory record Official record
Conditions
Social Discrimination, Sexual and Gender Minorities, Mindfulness
Interventions
Introduction Only, Purpose Only, Connection Only, Connection and Purpose, Awareness Only, Awareness and Purpose, Awareness, Purpose, and Connection, Awareness and Connection
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 29 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 17, 2026, 2:36 AM EDT
Recruiting Not applicable Interventional

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

NCT06974773
View directory record Official record
Conditions
Endometriosis
Interventions
NettleEndo, Sham NettleEndo Device
Device
Lead sponsor
Samphire Group, Inc.
Industry
Eligibility
22 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD

NCT05242367
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Modius Spero active device, Sham device
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

NCT00053599
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simvastatin
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2009 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

NCT00097916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
9
States / cities
San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 17, 2026, 2:36 AM EDT
Not listed Not applicable Interventional

Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions

NCT06190184
View directory record Official record
Conditions
Mental Health Issue, Mental Health Disorder, Mental Health, Depression, Depression, Anxiety, Anxiety, Anxiety Disorders, Anxiety Depression, Anxiety State
Interventions
VIOME Precision Nutrition Program, Control arm
Combination Product · Other
Lead sponsor
Viome
Industry
Eligibility
25 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 17, 2026, 2:36 AM EDT
Recruiting Phase 2 Interventional

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT06847321
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions
LHP588, Placebo Drug
Drug
Lead sponsor
Lighthouse Pharmaceuticals, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
38
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

NCT00940589
View directory record Official record
Conditions
Alzheimer's Disease, Sleep Disorder
Interventions
Circadin, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Brooksville, Florida • St. Petersburg, Florida • Mount Arlington, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

An Initial Test of Prototype Mobile App Interventions for Decluttering

NCT06108245
View directory record Official record
Conditions
Hoarding
Interventions
Values Clarification Mobile Application, Self-Reflection Mobile Application
Behavioral
Lead sponsor
Mississippi State University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Starkville, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

NCT00718731
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
GSI-136, Placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 17, 2026, 2:36 AM EDT
Terminated Phase 2 Interventional Results available

Fluphenazine Decanoate for Psoriasis

NCT00356200
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine Decanoate, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Sep 17, 2026, 2:36 AM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 17, 2026, 2:36 AM EDT
Completed Phase 1 Interventional

Bisnorcymserine in Healthy Adult Volunteers

NCT01747213
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BNC, Placebo
Drug · Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 2:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia

NCT06493825
View directory record Official record
Conditions
Tinnitus, Misophonia
Interventions
Aurora Mindfulness app versus sham
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 17, 2026, 2:36 AM EDT